Terumo Aortic’s Post

💬 "𝗦𝗵𝗼𝗰𝗸 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘄𝗶𝗹𝗹 𝗰𝗵𝗮𝗻𝗴𝗲 𝘁𝗿𝗲𝗺𝗲𝗻𝗱𝗼𝘂𝘀𝗹𝘆." - 𝗛𝗲𝗿𝗲 𝗶𝘀 𝘄𝗵𝗮𝘁 𝘆𝗼𝘂 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗸𝗻𝗼𝘄 𝗮𝗯𝗼𝘂𝘁 𝗘𝗦𝗖 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟰 ESC Congress is over, and we have all the hot topics for you that have been discussed during our #DanGer-sessions and the TEACH courses in our recap video. 💙 We would like to thank everybody who attended our fully booked courses and sessions and the exchange and activity within the scientific community surrounding our therapy. 💡What has been discussed around the #DanGerShockRCT: 🔹Patient Identification & Case-Based Discussion 🔹pVAD Support in Cardiogenic Shock Management on the ICU 🔹Optimizing Access & Closure for Percutaneous Mechanical Circulatory Support: Hands-On 🔹 Study Update 📝 About the TEACH course: About the TEACH course, Dr. Mark Dickstein held an interactive basic and advanced course on Training and Education in Advanced Cardiovascular Hemodynamics (TEACH). The course involved presentation elements, hands-on tasks, and interactive task reviews. 🚨 Stay tuned for individual recaps of our program! A special thank goes out to our dedicated team of booth stuff, trainers and speakers who made this congress a great success. #Impella #Abiomed #DanGerShock #CardiogenicShock

Key takeaways: 6 months is not a long time 🥸, however this news is encouraging 😁 🔹 Abbott’s Aveir DR leadless pacemaker, the world’s very first dual-chamber pacing solution of its kind, is associated with a “reliable” performance after six months, according to new data published in Heart Rhythm.[1] 🔷 The Aveir DR system includes both an atrial leadless pacemaker (ALP) and a ventricular leadless pacemaker (VLP). The two devices were designed to communicate with one another as needed, helping patients with abnormal heart rhythms receive the care they need at any given time. 🔹 The U.S. Food and Drug Administration (FDA) approved the new-look device in July 2023, making leadless pacing available to a much wider patient population. While single-chamber leadless pacing has been around for several years, most bradycardia patients require dual-chamber pacing.

Today I have had the privilege of working with a wonderfully dedicated S&L team. Our 2.2mm SteriScopes have allowed FEES tests to be carried out on some very mini patients. Our kit has eradicated the need to use X-Ray, enabled cost savings and eased timetabling implications. More importantly, reducing radiation indications and the risk of barium aspiration. Was it emotional? ✅ Was it less invasive for the patient? ✅ Was it safer? ✅ Was it more cost effective? ✅ Could the patient be diagnosed & treated? ✅ Anything is possible with the right approach. #FEES #paediatricintubation #creomedical

Thoroughly designed for lifetime management.

❤️ ZOLL Medical Corporation recruits first patient in SSO2 therapy trial in LAD STEMI heart attacks The study is named as SuperSaturated Oxygen Comprehensive Observational Registry (SSCORE). It aims to demonstrate the efficacy of SSO2 Therapy in lowering heart failure and mortality in patients with LAD STEMI. The SSCORE study will also gather data on potential healthcare cost savings from preventing heart failure, compared to long-term palliative treatments. The first patient in the trial was enrolled at the Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, a partner of Allina Health. 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

#ICYMI Our latest collaborative webinar is now ready to watch on demand. Gain insights on Interprofessional High-Fidelity Cardiopulmonary Resuscitation Simulation. Learn what it is, how to implement large-scale training, and key takeaways. Presented by experts from the University of Alabama.    Request Access:    #TrainWithGaumard #HealthcareTraining #MedEd #ClinicalEducation #Trauma 

More exciting news to share!

Key takeaways: 🔹 Abbott’s Aveir DR leadless pacemaker, the world’s very first dual-chamber pacing solution of its kind, is associated with a “reliable” performance after six months, according to new data published in Heart Rhythm.[1] 🔷 The Aveir DR system includes both an atrial leadless pacemaker (ALP) and a ventricular leadless pacemaker (VLP). The two devices were designed to communicate with one another as needed, helping patients with abnormal heart rhythms receive the care they need at any given time. 🔹 The U.S. Food and Drug Administration (FDA) approved the new-look device in July 2023, making leadless pacing available to a much wider patient population. While single-chamber leadless pacing has been around for several years, most bradycardia patients require dual-chamber pacing.

We are gratified by the enthusiasm around lymph-based diagnostics at MHNCS, where three prominent leaders in the field - Daniel Ma, MD, Eleni Rettig, MD, and Glenn Hanna, MD —discussed the promise of surgical drain fluid as a novel biofluid to inform patient care. We are excited to expand on this momentum and share more data at AACR. #HNCS24

"Of all the advancements in PE #thrombectomy, the FlowSaver is the biggest." Drs. Ripal Gandhi, M.D., FSVM, FSIR and Andrew Niekamp discuss how the #FlowSaver Blood Return System allows interventionalists to focus on clinically meaningful endpoints and treat patients more effectively. Learn more about FlowSaver, celebrating use with 70k+ patients. #SIR #FlowTriever